Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge,
MA 02139-4242
United States - Map
Phone: 617-444-6100
Fax: 617-576-2109
Web Site: http://www.vrtx.com
| Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Its product pipeline includes Telaprevir, a Phase III clinical trial product for the treatment of hepatitis C virus (HCV) infection; VX-813, a Phase Ia clinical trial product for chronic HCV infection; VX-985, which is under preclinical trails for chronic HCV infection; VX-770, a Phase IIa clinical trial candidate for the treatment of Cystic fibrosis; VX-809, a Phase Ib clinical trial product for the treatment of Cystic fibrosis; VX-509, a Phase Ia clinical trial product for immune-mediated inflammatory diseases; MK-5108 (VX-689), a Phase I clinical trial product for the treatment of cancer; and AVN-944(VX-944), which is in Phase 2 clinical trial for the treatment of cancer. The company also has development and commercial rights to VX-702 for the treatment of rheumatoid arthritis and other inflammatory diseases. It has collaboration agreements with Janssen Pharmaceutica, N.V.; Mitsubishi Tanabe Pharma Corporation; Cystic Fibrosis Foundation Therapeutics Incorporated; Merck & Co., Inc.; Avalon Pharmaceuticals, Inc.; GlaxoSmithKline plc.; and Bend Research Inc. Vertex Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Matthew Emmens , 57
Chairman, Chief Exec. Officer and Pres |
$
64.00K | N/A | Dr. Joshua S. Boger Ph.D., 57
Founder and Exec. Director |
$
1.69M |
$
2.76M | Mr. Ian F. Smith C.P.A., A.C.A., 43
Chief Financial Officer and Exec. VP |
$
835.00K |
$
1.55M | Mr. Kenneth S. Boger M.B.A., J.D., 62
Sr. VP, Sec. and Gen. Counsel |
$
713.00K |
$
0 | Dr. Peter R. Mueller Ph.D., 52
Chief Scientific Officer, Exec. VP of Global Research & Developement and Member of the Scientific Advisory Board |
$
841.00K |
$
227.00K |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.29% Nasdaq 
Profile
